Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
CGCullinan Therapeutics, Inc. logo

Cullinan Therapeutics, Inc. (CGEM)

NASDAQ Global Select · Currency in USD
$14.37 ▼ -0.55 (-3.69%)
At close: Oct 23, 4:00 PM ET. Market closed.
$14.37 ▲ +0.00 (+0.00%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$14.92
Open
$14.95
Day's Range
$13.86 – $14.95
52 Week Range
$6.73 – $23.19
Volume
485,201
Avg. Volume
929,680
Market Cap
$883.15M
Beta (5Y Monthly)
-0.01
PE Ratio (TTM)
--
EPS (TTM)
-$3.33
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$34.75

Profile: Cullinan Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
109
CEO
Nadim Ahmed

Cullinan Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for autoimmune diseases and cancer in the United States. It engages in the development of CLN-978, a CD19xCD3 bispecific T cell engager for autoimmune diseases in Phase 1 clinical trials; Velinotamig, a BCMAxCD3 bispecific T cell in Phase 1 clinical trials in patients with autoimmune diseases; and CLN-049, a FLT3xCD3 bispecific T cell engager, which is in Phase 1 clinical trials in patients with relapsed and refractory acute myeloid leukemia or myelodysplastic syndrome. The company is also developing Zipalertinib, an orally available small-molecule, irreversible epidermal growth factor receptor inhibitor in Phase 2b portion of the REZILIENT1 clinical trial in patients with EGFR ex20ins non-small cell lung cancer.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate -$0.84 · Revenue est. $2.00M
DateEst.Actual
Aug 6, 2026-$0.80-$0.81Miss
May 7, 2026-$0.84-$0.75Beat
Mar 10, 2026-$0.80-$0.77Beat
Nov 6, 2025-$0.95-$0.77Beat
Aug 7, 2025-$0.83-$1.07Miss
May 8, 2025-$0.78-$0.74Beat

Analyst view

Consensus price target
$34.75 ▲ +141.8%
Range $27.00 – $40.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on CGEM and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.